In this video, Aruna Padmanabhan, MD, discusses therapy combinations for the treatment of PIK3CA-mutated metastatic breast cancer.

In this video, Aruna Padmanabhan, MD, discusses the management of side effects seen in patients receiving PI3K inhibitors for ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

Although inhibitors targeting elements of the PI3K/AKT/mTOR pathway are promising approaches for leukemia therapy, there is an increasing consensus that these strategies will also have limited ...

Regor Pharmaceuticals Inc. has divulged phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, ...

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs ...

AZ’s success in bringing the AKT inhibitor to regulatory approval comes ... or death by 50% compared to Faslodex alone in this PI3K/AKT pathway biomarker-altered breast cancer population.

The main goal of our laboratory is the identification and characterization of signal transduction pathways that cause the dysregulation of growth and inhibition of apoptosis that characterize advanced ...

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...